Provided by Tiger Trade Technology Pte. Ltd.

XOMA Corp

41.71
+0.01000.02%
Post-market: 41.710.00000.00%17:40 EDT
Volume:78.31K
Turnover:3.27M
Market Cap:523.09M
PE:26.58
High:41.75
Open:41.56
Low:41.56
Close:41.70
52wk High:42.81
52wk Low:22.29
Shares:12.54M
Float Shares:6.56M
Volume Ratio:0.73
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.57
EPS(LYR):1.46
ROE:34.23%
ROA:1.28%
PB:5.64
PE(LYR):28.57

Loading ...

Xoma downgraded to Hold from Buy at Benchmark

TIPRANKS
·
May 22

XOMA Royalty Advances Merger Plans and Governance Changes

TIPRANKS
·
May 22

XOMA Royalty shareholders approve 2026 employee stock purchase plan with 500,000 shares

Reuters
·
May 22

XOMA Royalty amends merger agreement with Ligand Pharmaceuticals

TIPRANKS
·
May 18

XOMA Q1 net income falls to $4.5 million; total income and revenues slip to $12.32 million

Reuters
·
May 13

HC Wainwright Downgrades XOMA Royalty to Neutral From Buy, Adjusts Price Target to $39 From $97

MT Newswires Live
·
Apr 30

XOMA Royalty Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Apr 30

Xoma downgraded to Neutral from Buy at H.C. Wainwright

TIPRANKS
·
Apr 30

Deals of the day-Mergers and acquisitions

Reuters
·
Apr 28

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

Benzinga_recent_news
·
Apr 27

Ligand Pharma to Acquire XOMA, Expands Royalty Portfolio

TIPRANKS
·
Apr 27

Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million

Reuters
·
Apr 27

XOMA Shares Gain 9.7% After Co to Be Acquired by Ligand Pharmaceuticals for $739 Mln

THOMSON REUTERS
·
Apr 27

XOMA Royalty Corp - Stockholders to Receive One CVR per Share for 75% of Net Litigation Proceeds

THOMSON REUTERS
·
Apr 27

XOMA Royalty Corp - Ligand Increases 2026 Revenue Guidance to $270 Mln-$310 Mln; Royalties $225 Mln-$250 Mln

THOMSON REUTERS
·
Apr 27

XOMA Royalty Corp - Ligand Raises 2026 Adj EPS Guidance to $8.50-$9.50; Expects $1.50 Accretion to Adj EPS in 2027

THOMSON REUTERS
·
Apr 27

XOMA Royalty Corp - Ligand to Buy XOMA Royalty for $39.00 per Share in Cash, Equity Value $739 Mln

THOMSON REUTERS
·
Apr 27

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

GlobeNewswire
·
Apr 27

XOMA Shares Gain 5.4% Premarket After Report Ligand Pharmaceuticals Buying Co for Nearly $740 Mln

THOMSON REUTERS
·
Apr 27

BRIEF-Ligand Pharmaceuticals Is Buying Xoma For Nearly $740 Million - WSJ

Reuters
·
Apr 27